Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-03

Clinical Trial Update: Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone [Phase 3]

View source ↗

Summary

Phase 3 trial assessment of lubiprostone for opioid-induced bowel dysfunction has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LUBIPROSTONE (lubiprostone)

Snippet

Sponsor: Sucampo Pharma Americas, LLC | Conditions: Opioid-Induced Bowel Dysfunction | Phase 3 | Status: COMPLETED | Results posted: 2016-02-03